ADCs (Antibody Drug Conjugates) combines the best of two modalities, toxic efficacy, and antibody specificity. The result is an improved therapeutic window with fewer side effects. However, the bioanalytical requirements for PK analysis also require a multifaceted approach. Here we describe various mass spectrometry-based strategies Frontage has successfully applied in the bioanalysis of ADCs for clinical and preclinical studies.

In this webinar, Dr. Santosh Shah discusses the general industry standards for utilizing critical reagents in bioanalytical labs, importance of bridging various lots of critical reagents and maintaining stocks, and reviews proper storage, management, and documentation of critical reagents.

In this infographic, we share the emerging technologies beyond monoclonal antibodies and the bioanalytical methods to support the new technologies.